Cartesian Therapeutics Announces New Employment Inducement Grants
HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
Cartesian Therapeutics Presents Additional Retreatment Data Of Its Lead Investigational Asset, Descartes-08, In Patients With Generalized MG, During MGFA Scientific Session Of 2026 AANEM Annual Meeting
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target
Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Cartesian Therapeutics Q2 EPS $0.46 Beats $(0.86) Estimate
Cartesian Therapeutics Announces New Employment Inducement Grant
New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market
BTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price Target
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
Cartesian Therapeutics Inks Licensing Agreement With Westgene Biopharma For In Vivo Chimeric Antigen Receptor T-cell Therapies In Autoimmune Diseases, For Undisclosed Upfront And Milestone Payments
Needham Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $40
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
